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Introduction {#sec005}
============

Lipid lowering therapy is essential for prevention of major cardiovascular complications in patients diagnosed with cardiovascular disease (CVD), as well as in individuals at high cardiovascular risk \[[@pone.0183059.ref001], [@pone.0183059.ref002]\]. Although chronic kidney disease (CKD) is acknowledged as an independent risk factor for CVD \[[@pone.0183059.ref003]\], the benefit of lipid lowering therapy in CKD patients remains unclear and debatable. Several meta-analyses demonstrate that the effect of statin therapy is significantly modified by renal function \[[@pone.0183059.ref004], [@pone.0183059.ref005]\]. Recently, large-scale trials have investigated the clinical effect of statins in patients with CKD \[[@pone.0183059.ref006]--[@pone.0183059.ref008]\]. These trials proposed differing results of the effects of statins, depending on the severity of renal dysfunction. Two studies---the Deutsche Diabetes Dialyse Studie (4D), and A Study to Evaluate the Use of Rosuvastatin in Subjects on Regular Hemodialysis: An Assessment of Survival and Cardiovascular Events (AURORA) trials---which examined patients receiving hemodialysis, reported that statins were not beneficial in preventing cardiovascular complications \[[@pone.0183059.ref006], [@pone.0183059.ref007]\]. However, the Study of Heart and Renal Protection (SHARP) trial showed evidence of their clinical efficacy in a wide range of patients with CKD \[[@pone.0183059.ref008]\].

Although statins demonstrate a clinical effect on the secondary prevention of cardiovascular events, the above-mentioned trials did not focus on this benefit. Few studies have described the secondary preventive effects of statins after percutaneous coronary intervention (PCI) in patients with renal dysfunction \[[@pone.0183059.ref009]--[@pone.0183059.ref011]\]. However, most of these studies were performed on patients with mild renal dysfunction (estimated glomerular filtration rate \[eGFR\] ≤ 60 mL/min/1.73 m^2^ and \< 55.9 mL/min/1.73 m^2^) \[[@pone.0183059.ref009], [@pone.0183059.ref011]\]. An increasing body of evidence demonstrates that the pathophysiology of CVD differs based on the severity of renal dysfunction \[[@pone.0183059.ref012], [@pone.0183059.ref013]\]. Additionally, some studies report that as renal function declines, the effectiveness of lipid lowering therapy in prevention of CVD also decreases \[[@pone.0183059.ref012], [@pone.0183059.ref014]\]. Thus, further studies need to be performed in patients with advanced renal dysfunction (eGFR \< 30 mL/min/1.73 m^2^).

In this study, we evaluated the clinical impact of statins on major adverse cardiac events (MACEs) and all-cause mortality in patients with advanced renal dysfunction who had undergone PCI after acute myocardial infarction (AMI). Propensity score-matched analysis was performed to minimize the effect of a selection bias occurring due to the effect of potential confounders.

Methods {#sec006}
=======

Study population and design {#sec007}
---------------------------

Our study population was selected from the Korea Acute Myocardial Infarction Registry (KAMIR) database. Established in November 2005, and supported by the Korean Society of Cardiology, KAMIR is a prospective, observational, multicenter, web-based registry that includes AMI patients in Korea. The registry includes 53 centers with facilities for primary PCI. All data were accessed anonymously for analysis. Between November 2005 and July 2012, 33,205 patients diagnosed with AMI were enrolled in the KAMIR database. As shown in [Fig 1](#pone.0183059.g001){ref-type="fig"}, 1,776 patients diagnosed with advanced renal dysfunction, defined as eGFR less than 30 mL/min/1.73 m^2^, were eligible to be included in our study. We excluded patients with missing data regarding medications, in-hospital deaths, or those who were lost to follow-up within 12 months of being diagnosed with an AMI. Finally, 861 patients were enrolled in this study. Patients were divided into two groups (statin vs. no-statin group) based on whether they were prescribed statins as a discharge medication. Additionally, we performed a propensity score-matched analysis for treatment with statins. Details relating to propensity score-matched analysis are described below. The present study was performed based on the ethical guidelines of the 1975 Declaration of Helsinki, as revised in 2000. The study protocol was approved by the Institutional Review Board of all centers, and the approval number was 05--49 obtained from Chonnam National University Hospital. Written informed consent was obtained from all patients. The participating sites are listed in an appendix.

![Study flow chart.\
KAMIR, Korea Acute Myocardial Infarction Registry; eGFR, estimated glomerular filtration rate; AMI, acute myocardial infarction.](pone.0183059.g001){#pone.0183059.g001}

Definition and variables {#sec008}
------------------------

A serum creatinine level was measured prior to PCI, and renal function was assessed based on eGFR expressed as mL/min/1.73 m^2^ using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation \[[@pone.0183059.ref015]\]. Advanced renal dysfunction was defined as an eGFR \< 30 mL/min/1.73 m^2^. Baseline variables included age, gender, initial blood pressure, body mass index, and several cardiovascular risk factors such as hypertension, diabetes mellitus, dyslipidemia, and previous coronary artery disease (CAD). Laboratory findings including serum lipid profile and cardiac markers, and medications prescribed at discharge, were recorded.

Study outcomes {#sec009}
--------------

The primary study outcome was 12-month MACEs, which included cardiac death, recurrent myocardial infarction (MI), repeated PCI (target lesion or target vessel revascularization, or non-target vessel revascularization), and coronary artery bypass grafting (CABG). Cardiac death was defined as death attributable to arrhythmia or mechanical complications such as free wall rupture and ventricular septal rupture. Recurrent MI was defined as recurrent clinical features with new electrocardiographic findings that were compatible with MI, or increased levels of cardiac markers, these values being at least twice the upper limit of normal. We did not include planned revascularization as the primary study outcome. Secondary study outcome was an all-cause mortality during the 12-month follow-up. All-cause mortality included both cardiac and non-cardiac deaths.

Statistical analysis {#sec010}
--------------------

Continuous variables are presented as means ± standard deviations (SDs), and categorical data are reported as frequencies and percentages. Analysis of continuous variables was performed using the Student's t-test, and categorical data was analyzed using a Chi-square test or the Fisher's exact test. Survival curves were estimated by the Kaplan--Meier method and compared with the log-rank test. Multiple Cox proportional regression analysis determined the association of variables with 12-month MACEs, after adjusting for several confounders. The results are presented as hazard ratios (HRs) ± 95% confidence intervals (CI), and statistical significance is indicated. To reduce a potential selection bias and to balance differences between the two groups, a propensity score was estimated using a multivariable logistic regression model. Variables included in the logistic regression model used to deduce the propensity score were: age, gender, hypertension, dyslipidemia, Killip class, total cholesterol, low-density lipoprotein (LDL) cholesterol, N-terminal prohormone of brain natriuretic peptide, and discharge medications. The C-statistic for the propensity score derivation was 0.76. Statin and no-statin groups were subsequently matched using a 1:1 matching algorithm on the propensity scores. All statistical analyses were carried out using SPSS software version 19.0 (SPSS Inc., Chicago, IL, USA). A p value \< 0.05 was considered statistically significant.

Results {#sec011}
=======

Baseline characteristics, laboratory findings, and medications {#sec012}
--------------------------------------------------------------

Baseline characteristics, initial laboratory findings, and medications at discharge are presented in [Table 1](#pone.0183059.t001){ref-type="table"}. Among the 861 patients, 537 (62.4%) patients were treated with statins. The mean age of the study population was 69.4 years (age range: 18--100) and 477 (55.4%) were men. The statin group showed a higher prevalence of hypertension and dyslipidemia compared to the no-statin group. Patients belonging to the no-statin group had a poorer Killip class. Laboratory evaluation revealed that serum total cholesterol and LDL cholesterol values were significantly higher in the statin group. There were some significant differences between the two groups in terms of medications prescribed at discharge. After 1:1 propensity score-matching, 548 patients were matched. In the propensity score-matched populations, no significant differences were observed between the two groups with respect to baseline characteristics, laboratory findings, and medications.

10.1371/journal.pone.0183059.t001

###### Baseline characteristics of the study population.

![](pone.0183059.t001){#pone.0183059.t001g}

                                         Total population   p                 Propensity-matched population   p                                   
  -------------------------------------- ------------------ ----------------- ------------------------------- ----------------- ----------------- -------
      Age                                69.3 ± 11.3        69.6 ± 10.6       0.733                           69.8 ± 10.7       69.7 ± 10.6       0.842
      Gender (male)                      296 (55.1%)        181 (55.9%)       0.832                           145 (52.9%)       150 (54.7%)       0.668
      Body mass index (Kg/m^2^)          23.4 ± 3.4         23.0 ± 3.17       0.133                           23.3 ± 3.1        23.0 ± 3.2        0.399
      Systolic blood pressure (mm Hg)    133.7 ± 34.8       131.2 ± 33.9      0.318                           135.1 ± 36.3      131.9 ± 34.8      0.314
      Diastolic blood pressure (mm Hg)   78.1 ± 18.4        77.4 ± 18.9       0.567                           78.6 ± 17.7       77.5 ± 19.2       0.505
      Heart rate                         82.6 ± 22.6        82.5 ± 22.6       0.944                           84.3 ± 21.6       83.1 ± 22.4       0.531
      Killip class (more than II)        288 (53.6%)        203 (62.7%)       0.010                           167 (60.9%)       166 (60.6%)       0.930
  **Cardiovascular risk factors**                                                                                                                 
      Hypertension                       439 (81.9%)        246 (75.9%)       0.035                           214 (78.1%)       210 (76.6%)       0.683
      Diabetes mellitus                  310 (57.8%)        187 (57.7%)       0.973                           158 (57.5%)       157 (57.7%)       0.971
      Dyslipidemia                       94 (17.6%)         27 (8.4%)         \< 0.001                        23 (8.4%)         20 (7.3%)         0.634
      Current smoking                    165 (31.4%)        97 (30.2%)        0.712                           91 (33.7%)        85 (31.1%)        0.523
      Previous CAD                       165 (31.0%)        90 (27.9%)        0.329                           80 (29.2%)        76 (27.8%)        0.725
  **Laboratory findings**                                                                                                                         
      LVEF (%)                           48.04 ± 12.8       46.7 ± 13.1       0.168                           47.2 ± 13.1       47.2 ± 12.9       0.952
      Glucose (mg/dl)                    210.1 ± 119.7      205.9 ± 118.4     0.631                           223.4 ± 129.6     209.0 ± 122.9     0.185
      Creatinine (mg/dl)                 4.7 ± 4.2          4.6 ± 3.7         0.901                           4.7 ± 4.2         4.6 ± 3.4         0.657
      Estimated GFR (ml/min/1.73 m^2^)   17.1 ± 8.8         16.6 ± 8.8        0.451                           17.0 ± 8.8        16.7 ± 8.7        0.693
      Maximal CK-MB (U/L)                72.4 ± 119.1       66.9 ± 125.7      0.526                           72.2 ± 122.6      67.9 ± 129.2      0.689
      Maximal TnI (ng/ml)                31.7 ± 57.6        28.9 ± 74.8       0.566                           33.4 ± 65.6       28.0 ± 73.7       0.388
      Total cholesterol (mg/dl)          171.1 ± 49.8       158.9 ± 43.2      \< 0.001                        160.2 ± 41.6      158.5 ± 43.3      0.632
      Triglyceride (mg/dl)               127.5 ± 80.4       119.5 ± 74.6      0.148                           121.0 ± 85.7      118.9 ± 75.3      0.757
      HDL cholesterol (mg/dl)            40.3 ± 12.2        39.7 ± 12.3       0.514                           40.5 ± 12.4       39.7 ± 12.4       0.457
      LDL cholesterol (mg/dl)            103.2 ± 43.7       93.1 ± 39.1       0.002                           95.3 ± 36.1       93.0 ± 95.3       0.484
      hsCRP (mg/dl)                      10.9 ± 29.7        8.9 ± 22.6        0.348                           12.8 ± 34.1       9.1 ± 23.1        0.167
      NT-proBNP (pmol/L)                 1648.3 ± 1568.5    2004.2 ± 1768.5   0.014                           1710.0 ± 1641.1   2007.3 ± 1808.3   0.117
      HbA1C (%)                          6.8 ± 1.3          6.9 ± 1.9         0.707                           6.8 ± 1.2         6.8 ± 1.9         0.822
  **Discharge medications**                                                                                                                       
      Aspirin                            523 (97.4%)        296 (91.4%)       \< 0.001                        262 (95.6%)       255 (93.1%)       0.196
      Clopidogrel                        487 (90.7%)        268 (82.7%)       0.001                           238 (86.9%)       227 (82.8%)       0.190
      Calcium-channel blocker            108 (20.4%)        87 (26.9%)        0.028                           71 (25.9%)        74 (27.0%)        0.771
      Beta-blocker                       410 (76.9%)        220 (67.9%)       0.023                           190 (49.5%)       194 (50.5%)       0.709
      ACE inhibitor                      242 (45.7%)        130 (40.2%)       0.116                           126 (46.3%)       119 (43.6%)       0.521
      ARB                                193 (36.3%)        104 (32.3%)       0.229                           109 (39.8%)       92 (33.7%)        0.140

CAD, coronary artery disease; LVEF, left ventricular ejection fraction; GFR, glomerular filtration rate; CK-MB, creatine kinase MB; TnI, troponin I; HDL, high-density lipoprotein; LDL, low-density lipoprotein; hsCRP, high-sensitivity C-reaction protein; NT-proBNP, N-terminal prohormone of brain natriuretic peptide; HbA1c, hemoglobin A1c; ACE, angiotensin converting enzyme; ARB, angiotensin receptor blocker

Clinical outcomes in the total population {#sec013}
-----------------------------------------

Clinical outcomes in the total and propensity score-matched population are shown in [Table 2](#pone.0183059.t002){ref-type="table"}. During the 12-month follow-up period, 199 (23.1%) patients experienced MACEs. Of the 199 patients, cardiac death was noted in 113 (56.8%), 31 (15.6%) showed recurrent MI, 49 (24.6%) needed a repeated PCI, and 6 (3.0%) patients underwent CABG. Prevalence of 12-month overall MACEs or all-cause mortality was not significantly different between the two groups ([Fig 2A and 2B](#pone.0183059.g002){ref-type="fig"}). No significant differences were observed in rates of recurrent MI, repeated PCI, or CABG between the two groups. However, the cardiac death rate was significantly lower in the statin group compared to the no-statin group (10.8% vs. 17.0%, p = 0.009). [Fig 2C](#pone.0183059.g002){ref-type="fig"} shows 12-months cardiac death-free survival. The log-rank test identified that there was a significant association between statin usage and cardiac death-free survival (p = 0.013). Cox-regression analysis revealed that stain usage was not significantly associated with the incidence of 12-month MACEs ([S1 Table](#pone.0183059.s001){ref-type="supplementary-material"})

![Event-free survival curves in total population.\
MACE, major adverse cardiac event; HR, hazard ratio; CI, confidence interval.](pone.0183059.g002){#pone.0183059.g002}
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###### Clinical outcomes in total and propensity-score matched population.

![](pone.0183059.t002){#pone.0183059.t002g}

                        Total population   p            Propensity score-matched population   p                         
  --------------------- ------------------ ------------ ------------------------------------- ------------ ------------ -------
  Overall MACEs         115 (21.4%)        84 (25.9%)   0.128                                 75 (27.4%)   74 (27.0%)   0.924
  Cardiac death         58 (10.8%)         55 (17.0%)   0.009                                 37 (13.5%)   51 (18.6%)   0.103
  Recurrent MI          21 (3.9%)          10 (3.1%)    0.529                                 11 (4.0%)    7 (2.6%)     0.338
  Repeated PCI          31 (5.8%)          18 (5.6%)    0.894                                 24 (8.8%)    15 (5.5%)    0.135
  CABG                  5 (0.7%)           1 (0.3%)     0.287                                 3 (1.1%)     1 (0.4%)     0.316
  All-cause mortality   94 (17.5%)         72 (22.2%)   0.089                                 51 (18.6%)   62 (22.6%)   0.245

MACE, major adverse cardiovascular event; MI, myocardial infarction; PCI, percutaneous coronary intervention; CABG, coronary artery bypass grafting.

Clinical outcomes in the propensity score-matched population {#sec014}
------------------------------------------------------------

There were no significant differences in the rates of 12-month overall MACEs or all-cause mortality in the propensity score-matched population ([Table 2](#pone.0183059.t002){ref-type="table"}, [Fig 3A and 3B](#pone.0183059.g003){ref-type="fig"}). Furthermore, the prevalence of recurrent MI, repeated PCI, and/or CABG was not significantly different between the two groups. Unlike findings observed in the total population, no significant difference was seen with respect to cardiac death in the propensity score-matched population ([Fig 3C](#pone.0183059.g003){ref-type="fig"}). Cox-regression analysis revealed that stain usage did not significantly reduce the incidence of 12-month MACEs or all-cause mortality ([Table 3](#pone.0183059.t003){ref-type="table"}). After adjustment, the left ventricular ejection fraction (LVEF) was the only factor that was independently associated with 12-month MACEs. Higher LVEF has a protective effect on MACEs (HR 0.979, 95% CI 0.962--0.996, p = 0.018).

![Event-free survival curves in propensity score--matched population.\
MACE, major adverse cardiac event; HR, hazard ratio; CI, confidence interval.](pone.0183059.g003){#pone.0183059.g003}
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###### Predictors of MACEs in univariate and multivariate Cox regression analyses in propensity-matched population.

![](pone.0183059.t003){#pone.0183059.t003g}

  Variable                      Univariate analysis    Multivariate analysis                          
  ----------------------------- ---------------------- ----------------------- ---------------------- -------
  Age                           1.011 (0.996--1.027)   0.155                                          
  Gender                        0.796 (0.577--1.097)   0.163                                          
  Body mass index               0.985 (0.936--1.041)   0.635                                          
  Systolic blood pressure       1.000 (0.995--1.004)   0.860                                          
  Diastolic blood pressure      0.993 (0.984--1.002)   0.107                                          
  Heart rate                    0.999 (0.992--1.007)   0.853                                          
  Killip class (more than II)   1.208 (0.865--1.687)   0.267                                          
  Hypertension                  1.394 (0.919--2.116)   0.118                                          
  Diabetes mellitus             1.535 (1.092--2.156)   0.014                   1.410 (0.930--2.137)   0.106
  Dyslipidemia                  1.443 (0.847--2.461)   0.178                                          
  Smoking                       0.836 (0.587--1.192)   0.323                                          
  Previous CAD                  1.246 (0.883--1.765)   0.210                                          
  LVEF                          0.972 (0.959--0.986)   \< 0.001                0.979 (0.962--0.996)   0.018
  Glucose                       1.001 (1.000--1.002)   0.128                                          
  Estimated GFR                 1.004 (0.986--1.022)   0.692                                          
  Max CK-MB                     0.999 (0.997--1.000)   0.091                   1.000 (0.998--1.002)   0.615
  Max TnI                       0.999 (0.996--1.002)   0.475                                          
  Total Cholesterol             1.000 (0.996--1.004)   0.984                                          
  Triglyceride                  1.000 (0.999--1.002)   0.613                                          
  HDL-cholesterol               1.003 (0.991--1.016)   0.618                                          
  LDL-cholesterol               0.999 (0.994--1.003)   0.545                                          
  hsCRP                         0.999 (0.993--1.006)   0.834                                          
  NT-proBNP                     1.000 (1.000--1.000)   0.136                                          
  HbA1C                         1.026 (0.867--1.214)   0.766                                          
  Aspirin                       1.476 (0.652--3.340)   0.350                                          
  Clopidogrel                   1.273 (0.787--2.060)   0.326                                          
  Calcium-channel blocker       0.784 (0.535--1.150)   0.213                                          
  Beta-blocker                  1.601 (1.088--2.357)   0.017                   1.472 (0.898--2.413)   0.125
  ACE inhibitor                 0.887 (0.641--1.227)   0.468                                          
  ARB                           0.850 (0.605--1.194)   0.349                                          
  Statin                        1.018 (0.738--1.404)   0.913                                          

CAD, coronary artery disease; LVEF, left ventricular ejection fraction; GFR, glomerular filtration rate; CK-MB, cratine kinase MB; TnI, troponin I; HDL, high-density lipoprotein; LDL, low-density lipoprotein; hsCRP, high-sensitivity C-reaction protein; NT-proBNP, N-terminal prohormone of brain natriuretic peptide; HbA1c, hemoglobin A1c; ACE, angiotensin converting enzyme; ARB, angiotensin receptor blocker

Discussion {#sec015}
==========

This study investigated the clinical effects of statin therapy on 12-month MACEs or all-cause mortality in patients with advanced renal dysfunction who underwent PCI after AMI. To the best of our knowledge, this is the first study to demonstrate a correlation between statins and clinical outcomes in patients with advanced renal dysfunction, using propensity score-matched analysis and the CKD-EPI equation. Our principal findings were: (1) Statin therapy did not reduce 12-month MACEs or all-cause mortality in patients with advanced renal dysfunction (eGFR \< 30 mL/min/ 1.73m^2^) who underwent PCI after AMI. (2) Although a significant reduction in cardiac death rate was observed in the statin group of the total population, the statistical significance diminished when propensity score-matching analysis was used. (3) LVEF was an independent predictor of 12-month MACEs in patients with advanced renal dysfunction undergoing PCI after AMI.

Previous studies have proved the benefits of lipid lowering therapies with respect to cardiovascular outcomes, with statins being the mainstay of this therapy \[[@pone.0183059.ref016], [@pone.0183059.ref017]\]. Although a strong body of evidence supports the cardiovascular benefits of statins in the general population, the significance of statin use in patients with renal dysfunction is unclear \[[@pone.0183059.ref005]\]. Studies performed on patients with early-stage CKD have generally reported beneficial effects of statins on cardiovascular outcomes \[[@pone.0183059.ref008], [@pone.0183059.ref018]\]. However, statins habe not been conclusively shown to reduce the incidence of cardiovascular events in patients with advanced-stage CKD \[[@pone.0183059.ref006], [@pone.0183059.ref007]\]. These results suggest that the benefit of statins on cardiovascular outcomes in patients with renal disease depends up on the severity of renal dysfunction. Few studies have demonstrated the effect of statin therapy on clinical outcomes in patients with CKD after AMI. Moreover, studies that investigated the effect of statins in patients with CKD who underwent PCI are also limited \[[@pone.0183059.ref009]--[@pone.0183059.ref011]\].

In the present study, we examined the effects of statin therapy on cardiovascular outcomes and all-cause mortality in patients with advanced CKD who underwent PCI for AMI. Statins were not conclusively shown to demonstrate beneficial effects on clinical outcomes, and our finding was similar to results obtained from previous studies \[[@pone.0183059.ref010]\]. Although the exact mechanisms to explain these results could not be determined, a hypothetical explanation base on speculation could be offered. Several studies suggest that pathogenesis of CVD differs in patients with CKD \[[@pone.0183059.ref012]\]. Traditional risk factors alone do not explain the higher cardiovascular morbidity and mortality observed in patients with CKD \[[@pone.0183059.ref019]\]. Other contributory factors such as indlammation, volume overload, anemia, as well as calcium and phosphorus imbalance may have a greater effect on the outcomes of cardiovascular disease in CKD patients \[[@pone.0183059.ref020], [@pone.0183059.ref021]\]. Additionally, malnutrition may worsen cardiovascular outcomes in a patient by aggravating existing inflammation and heart failure, accelerating atherosclerosis, and increasing susceptibility to infection \[[@pone.0183059.ref022]\]. Statins might be ineffective in patients with advanced CKD but might have some role in patients with mild CKD. A possible explanation could be that unconventional contributory risk factors worsen as the disease progresses. We additionally analyzed the clinical effect of statins by dividing the patient population into quartiles based on eGFR \[quartile 1 (eGFR ≥ 90 mL/min/1.73m^2^), quartile 2 (eGFR ≥ 60 to \< 90 mL/min/1.73m^2^), quartile 3 (eGFR ≥ 30 to \< 60 mL/min/1.73m^2^), and quartile 4 (eGFR \< 30 mL/min/1.73m^2^)\]. The significant beneficial effect of statins was only observed in patients with eGFR ≥ 90 mL/min/1.73m^2^ ([S2 Table](#pone.0183059.s002){ref-type="supplementary-material"}).

Prior to performing propensity score-mating, the total cholesterol and LDL cholesterol levels at baseline were noted to be higher in the statin group. Malnutrition could aggravate existing inflammation, thereby contributing to the increased cardiovascular risk in CKD patients. Thus, a higher lipid profile, which indicates a good nutritional status could be a confounding factor while estimating the effect of statin treatment. Therefore, we performed propensity matching using 1:1 propensity score-matching; thus, eliminating confounders including lipid profiles. After propensity matching and elimination of confounders, we could accurately estimate the role of statin treatment in patients with advanced CKD who had been diagnosed with an AMI. We found that statin therapy after MI was not significantly effective for 12-month MACEs or all-cause mortality, and LVEF was the only independent predictor of risk. LVEF represents left ventricle systolic function and is acknowledged to be associated with a mortality risk after MI \[[@pone.0183059.ref023]\]. In patients with AMI, LVEF may reflect a higher degree of myocardial damage or myocardial stunning \[[@pone.0183059.ref024]\]. La Rovere et al. \[[@pone.0183059.ref025]\] have reported that patients with a low LVEF (\< 35%) had a relatively higher risk of cardiac morality compared to patients with a high LVEF (\> 50%) after an MI. Another recent study has shown that LVEF ≤ 30% effectively predicted cardiac and all-cause mortality in acute MI survivors \[[@pone.0183059.ref026]\]. In this study, the hazard ratio of LVEF for 12-month MACEs is close to 1, indicating that LVEF might not relevant in daily practice. However, considering 95% CI, it is difficult to assume that LVEF does not possess a good predictive value.

Using multivariate analysis, we failed to establish a significant association between some traditional risk factors and MACEs. Possible suppositions for this phenomenon could be: Our study population comprised only patients with advanced renal dysfunction (eGFR \< 30 mL/min/1.73 m^2^). Some studies have failed to reveal a significant association between traditional risk factors and CVD in patients with advanced renal dysfunction \[[@pone.0183059.ref019], [@pone.0183059.ref027]\]. Additionally, as previously reported, the triglyceride to high-density lipoprotein cholesterol ratio failed to predict MACEs after AMI in patients with renal dysfunction \[[@pone.0183059.ref028]\]. We hypothesized that the above-mentioned conventional and unconventional risk factors have an additive effect in increasing the susceptibility of CKD patients to CVD.

There are some limitations in our study. First, we used the eGFR value instead of directly measuring the glomerular filtration rate (GFR). This could lead to an over- or underestimation of renal function. Second, serum creatinine was measured only once, which could result in an incorrect classification of patients. Although we tried to address this problem, we could not obtain additional data because of the features of the database. We will try to eliminate these drawbacks in our next study using multiple data point collection. Third, we did not have information on the dosages and types of statins administered. Although these factors were considered during analyses, we were unable to obtain complete information. Fourth, participants were not randomized and study was performed on a very specific population. There might be some differences between our study population and members of the general population with renal dysfunction. Of the 33,205 patients who underwent PCI for AMI between November 2005 and July 2012, 1,776 patients with advanced renal dysfunction were selected for this study. The effect of underpowered analysis cannot be denied. However, considering previous studies performed on AMI patients in Korea \[[@pone.0183059.ref029]\], the prevalence of advanced renal dysfunction in our study is no significantly different. After excluding the ineligible population, 861 patients were found to be eligible for this study. We selected 548 patients using 1:1 propensity score-matching to minimize a selection bias. Finally, we did not assess the long-term clinical outcomes, and did not state the improvement in clinical outcomes after administration of statins. Prospective clinical studies including data that represent improvement of clinical outcomes and studies with a longer follow-up period need to be performed.

There are also some strengths to this study. First, unlike most previous studies which used the Modification of Diet in Renal Disease (MDRD) study equation, we used the recently introduced CKD-EPI equation to calculate the eGFR. This equation uses the same variables (serum creatinine, age, gender, and race) as the MDRD study equation, but applies different coefficients \[[@pone.0183059.ref015]\]. The CKD-EPI equation reportedly more accurately categorizes mortality risk compared to the MDRD study equation \[[@pone.0183059.ref030]\]. Second, we performed propensity score-matching analysis. We performed 1:1 matching using the greedy and nearest neighbor algorithm method. In this manner, we could reduce the differences between the two groups and minimize any selection bias. Finally, ours was a population-based study that included a large number of patients.

In conclusion, statin therapy did not significantly reduce the 12-month MACEs or all-cause mortality in patients with advanced renal dysfunction undergoing PCI after AMI. Further longitudinal and comparative studies are required to reliably evaluate the effect of statins in this patient population.

Appendix {#sec016}
========

Institutional review board of participating sites {#sec017}
-------------------------------------------------

The Korea Acute Myocardial Infarction Registry (KAMIR) was approved by the institutional review board (IRB) at each participating center (Kyunghee University IRB, Asan Medical Center IRB, Ajou University Hospital IRB, Busan Hanseo Hospital IRB, Busan National University Hospital IRB, Choongbook National University Hospital IRB, Chungnam National University Hospital IRB, Catholic University Hospital IRB, Chonbuk National University Hospital IRB, Chosun University Hospital IRB, Chung-Ang University Hospital IRB, Dankook University Hospital IRB, Daegu Catholic University Medical Center IRB, Dong-A University Medical Center IRB, Daejeon St. Mary\'s Hospital IRB, Dongguk University Gyeongju Hospital IRB, Gyeongsang National University Hospital IRB, Hallym University Kandong Sacred Heart Hospital IRB, Hallym University Sacred Heart Hospital IRB, Inje University Haeundae Paik hospital IRB, Inje University Sanggye Paik Hospital IRB, Inha University Hospital IRB, Jeju National University Hospital IRB, Kyungpook National University Hospital IRB, Keimyung University Hospital IRB, Korea University Guro Hospital IRB, Konyang University Hospital IRB, Kwangju Christian Hospital IRB, Maryknoll Medical Center IRB, National Health Insurance Corporation Ilsan Hospital IRB, Yeungnam University Hospital IRB, Yonsei University Severance Hospital IRB, Yonsei University Wonju Hospital IRB, Presbyterian Medical Center IRB, Seoul National University Hospital IRB, Seoul National University Bundang Hospital IRB, Soon Chun Hyang University Bucheon Hospital IRB, Soon Chun Hyang University Cheonan Hospital IRB, Samsung Medical Center IRB, Sun General Hospital IRB, Saint Carollo Hospital IRB, Wonkwang University Hospital IRB and Chonnam National University Hospital IRB).
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